Investigational Drug Information for CS-3150
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug CS-3150?
CS-3150 is an investigational drug.
There have been 11 clinical trials for CS-3150.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Hypertension, Essential Hypertension, and Renal Insufficiency. The leading clinical trial sponsors are Daiichi Sankyo Co., Ltd., Daiichi Sankyo, Inc., and Daiichi Sankyo Inc.
There are twenty US patents protecting this investigational drug and two hundred and seventeen international patents.
Summary for CS-3150
US Patents | 20 |
International Patents | 217 |
US Patent Applications | 56 |
WIPO Patent Applications | 46 |
Japanese Patent Applications | 13 |
Clinical Trial Progress | Phase 3 (2016-06-01) |
Vendors | 20 |
Recent Clinical Trials for CS-3150
Title | Sponsor | Phase |
---|---|---|
Study of CS-3150 in Patients With Primary Aldosteronism | Daiichi Sankyo Co., Ltd. | N/A |
Study of CS-3150 in Patients With Essential Hypertension | Daiichi Sankyo Co., Ltd. | Phase 3 |
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension | Daiichi Sankyo Co., Ltd. | N/A |
Clinical Trial Summary for CS-3150
Top disease conditions for CS-3150
Top clinical trial sponsors for CS-3150
US Patents for CS-3150
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
CS-3150 | See Plans and Pricing | Method for producing pyrrole derivative, and intermediate thereof | Daiichi Sankyo Company, Limited (Chuo-ku, JP) | See Plans and Pricing |
CS-3150 | See Plans and Pricing | Solid composition of pyrrole carboxamide | Daiichi Sankyo Company, Limited (Chuo-ku, JP) | See Plans and Pricing |
CS-3150 | See Plans and Pricing | Pharmaceutical for prophylaxis or treatment of hypertension | Daiichi Sankyo Company, Limited (Chuo-ku, JP) | See Plans and Pricing |
CS-3150 | See Plans and Pricing | Method for producing pyrrole derivative, and intermediate thereof | Daiichi Sankyo Company, Limited (Chuo-ku, JP) | See Plans and Pricing |
CS-3150 | See Plans and Pricing | Amide-substituted pyridinyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | See Plans and Pricing |
CS-3150 | See Plans and Pricing | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | See Plans and Pricing |
CS-3150 | See Plans and Pricing | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (Leverkusen, DE) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CS-3150
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
CS-3150 | Canada | CA2922350 | 2033-08-27 | See Plans and Pricing |
CS-3150 | China | CN105473552 | 2033-08-27 | See Plans and Pricing |
CS-3150 | European Patent Office | EP3040330 | 2033-08-27 | See Plans and Pricing |
CS-3150 | Spain | ES2660988 | 2033-08-27 | See Plans and Pricing |
CS-3150 | Hungary | HUE037007 | 2033-08-27 | See Plans and Pricing |
CS-3150 | Japan | JP6422871 | 2033-08-27 | See Plans and Pricing |
CS-3150 | Japan | JPWO2015030010 | 2033-08-27 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |